Zynerba Pharmaceuticals Reveals Positive Results From Phase 2 INSPIRE Trial Of Zygel In 22q11.2 Deletion Syndrome
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) revealed positive top line results from the exploratory, open label Phase 2 INSPIRE trial. Based on the positive Phase 2 data, the company will request a meeting with the U.S.